Drugs / APL-501
APL-501
also known as
GB226 · Geptanolimab · CBT-501 · Genolimzumab · Geptanolimab Injection · Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection
Monoclonal antibody targets PDCD1 via inhibition
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03976856 | Jul 2019 → Dec 2021 | non-small cell lung carcinoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03977090 | Apr 2019 → Dec 2021 | colorectal cancer | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03374007 | Oct 2017 → Jun 2022 | Hodgkin's lymphoma, lymphocytic depletion | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03053466 | Mar 2017 → Feb 2022 | cancer of unknown primary site | Apollomics (Australia) Pty. Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03655613 | Sep 2018 → Dec 2021 | hepatocellular carcinoma, renal cell carcinoma | Apollomics (Australia) Pty. Ltd. | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05873244 | Aug 2023 → Dec 2027 expected | hepatocellular carcinoma | Stephen Chan Lam | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03808857 | May 2019 → Dec 2021 | cervical cancer | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03639181 | Oct 2018 → Sep 2021 | B-cell non-Hodgkin lymphoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03623581 | Sep 2018 → Aug 2021 | alveolar soft part sarcoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03502629 | Jul 2018 → Aug 2021 | peripheral T-cell lymphoma, not otherwise specified | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03655613 ↗ |
| Known as | CBT-501 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594355 ↗ |
| Known as | GB226 | “Recombinant Programmed death-1(PD-1) humanized monoclonal antibody injection (company code: GB226) is joint developed by Genor Biopharma Co. Ltd and Crown Bioscience,Inc.” NCT03374007 ↗ |
| Known as | Genolimzumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594355 ↗ |
| Known as | Geptanolimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03977090 ↗ |
| Known as | Geptanolimab Injection | “Geptanolimab Injection 1mg/kg” NCT03374007 ↗ |
| Known as | Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection | “Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection” NCT03374007 ↗ |
| Action | Inhibit | “Programmed cell death protein 1 inhibitor” CHEMBL4594355 ↗1“anti-PD-1 antibody” PMID 40199606 ↗ Apr 2025 |
| Modality | Monoclonal antibody | “humanized monoclonal antibody injection” NCT03374007 ↗ |
| Route | Intravenous | “i.v.” NCT03374007 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1 inhibitor” CHEMBL4594355 ↗ |